Skip to main content

Advertisement

SpringerLink
Log in

Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

VX-710 (biricodar, Incel) restores drug sensitivity to cells expressing P-glycoprotein (P-gp) and multidrug resistance-associated protein (MRP1). MRP1 is expressed in a high proportion of prostate tumors while P-gp expression is variable. Since mitoxantrone (M) and prednisone (P) are substrates for MDR transporters, we initiated a study to evaluate the safety, pharmacokinetics, and efficacy of VX-710 plus M/P in patients with hormone-refractory prostate cancer (HRPC).

Patients and methods

Eligible patients had progressive HRPC (defined as new lesions, new disease-related pain, or 50% increase in PSA within 6 weeks of entry), testosterone <30 ng/ml, no prior chemotherapy, ECOG performance status of 0–3, and adequate organ function. Patients received VX-710 (120 mg/m2 per h) as a 72-h continuous intravenous infusion with intravenous bolus mitoxantrone (12 mg/m2) administered 4 h after VX-710 was started and prednisone (5 mg twice daily) administered throughout the study treatment. Endpoints included serum PSA response, PSA response duration, time to PSA progression, pain reduction, and quality of life measures.

Results

Enrolled in the study were 40 patients and 184 courses of VX-710 plus M/P were administered. Intensive pharmacokinetics, which were performed on six patients who received one cycle of M/P alone, followed by VX-710 plus M/P for all other cycles, showed that VX-710 did not alter mitoxantrone clearance. VX-710 blood concentration at the time of mitoxantrone administration averaged 4.52 μg/ml. VX-710 plus M/P was well tolerated. Transient nausea/vomiting and mild neutropenia were the principal treatment toxicities. Five patients experienced an uncomplicated febrile neutropenic episode (12%), three had severe nausea/vomiting, and two experienced transient moderate to severe ataxia. Of the 40 patients, 12 (30%, 95% confidence interval 16–44%) had a reduction in PSA of ≥50% and 9 of the 12 patients (23% overall, 95% CI 10–35%) achieved a reduction in PSA of ≥80% that was sustained for the duration of treatment with M/P plus VX-710. The median time to PSA progression was 41 weeks (95% CI 34–68 weeks). Of the 40 patients, 15 completed treatment with stable disease and 13 had progressive disease with increasing serum PSA during study treatment. Median survival was 48 weeks for the intent-to-treat population of 40 patients.

Conclusions

The addition of VX-710 to M/P therapy did not appear to increase the proportion of patients with significant serum PSA reductions compared to M/P alone. However, the duration of PSA response observed for the 12 PSA responders suggests that MDR inhibition may benefit some patients with HRPC. In addition to MRP1 or P-gp expression, other mechanisms of drug resistance are probably associated with the relative insensitivity of HRPC to cytotoxic therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1.
Fig. 2.

Similar content being viewed by others

References

  1. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM (1999) Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 39:361

    CAS  PubMed  Google Scholar 

  2. Batra S, Karlsson R, Witt L (1996) Potentiation by estramustine of the cytotoxic effect of vinblastine and doxorubicin in prostatic tumor cells. Int J Cancer 68:644

    Article  CAS  PubMed  Google Scholar 

  3. Bhangal G, Halford S, Wang J, Roylance R, Shah R, Waxman J (2000) Expression of the multidrug resistance gene in human prostate cancer. Urol Oncol 5:118

    Article  PubMed  Google Scholar 

  4. Borst P, Evers R, Kool M, Wijnholds J (2000) A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 92:1295

    CAS  PubMed  Google Scholar 

  5. Bradshaw DM, Arceci RJ (1998) Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance. J Clin Oncol 16:3674

    CAS  PubMed  Google Scholar 

  6. Bramwell VH, Morris D, Ernst DS, Hings I, Blackstein M, Venner PM, Ette EI, Harding MW, Waxman A, Demetri GD (2002) Safety and efficacy of the multidrug-resistance inhibitor biricodar (VX-710) with concurrent doxorubicin in patients with anthracycline-resistant advanced soft tissue sarcoma. Clin Cancer Res 8:383–393

    CAS  PubMed  Google Scholar 

  7. Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, Figg WD, Freidlin B, Halabi S, Hudes G, Hussain M, Kaplan R, Myers C, Oh W, Petrylak DP, Reed E, Roth B, Sartor O, Scher H, Simons J, Sinibaldi V, Small EJ, Smith MR, Trump DL, Wilding G (1999) Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 17:3461

    CAS  PubMed  Google Scholar 

  8. Chaudhary PM, Roninson IB (1991) Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 66:85

    CAS  PubMed  Google Scholar 

  9. Cole SP, Sparks KE, Fraser K, Loe DW, Grant CE, Wilson GM, Deeley RG (1994) Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res 54:5902

    CAS  PubMed  Google Scholar 

  10. Culine S, Droz JP (2000) Chemotherapy in advanced androgen-independent prostate cancer 1990–1999: a decade of progress? Ann Oncol 11:1523

    Article  CAS  PubMed  Google Scholar 

  11. Drach D, Zhao S, Drach J, Mahadevia R, Gattringer C, Huber H, Andreeff M (1992) Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistant phenotype. Blood 80:2729

    CAS  PubMed  Google Scholar 

  12. Ehninger G, Schuler U, Proksch B, Zeller KP, Blanz J (1990) Pharmacokinetics and metabolism of mitoxantrone. A review. Clin Pharmacokinet 18:365

    CAS  PubMed  Google Scholar 

  13. Ferry DR, Traunecker H, Kerr DJ (1996) Clinical trials of P-glycoprotein reversal in solid tumours. Eur J Cancer 32A: 1070

    Article  CAS  PubMed  Google Scholar 

  14. Flens MJ, Zaman GJ, van der Valk P, Izquierdo MA, Schroeijers AB, Scheffer GL, van der Groep P, de Haas M, Meijer CJ, Scheper RJ (1996) Tissue distribution of the multidrug resistance protein. Am J Pathol 148:1237

    CAS  PubMed  Google Scholar 

  15. Germann UA, Ford PJ, Shlyakhter D, Mason VS, Harding MW (1997) Chemosensitization and drug accumulation effects of VX-710, verapamil, cyclosporin A, MS-209 and GF120918 in multidrug resistant HL60/ADR cells expressing the multidrug resistance-associated protein MRP. Anticancer Drugs 8:141

    CAS  PubMed  Google Scholar 

  16. Germann UA, Shlyakhter D, Mason VS, Zelle RE, Duffy JP, Galullo V, Armistead DM, Saunders JO, Boger J, Harding MW (1997) Cellular and biochemical characterization of VX-710 as a chemosensitizer: reversal of P-glycoprotein-mediated multidrug resistance in vitro. Anticancer Drugs 8:125

    CAS  PubMed  Google Scholar 

  17. Hipfner DR, Deeley RG, Cole SP (1999) Structural, mechanistic and clinical aspects of MRP1. Biochim Biophys Acta 1461:359

    CAS  PubMed  Google Scholar 

  18. Hudes GR, Nathan F, Khater C, Haas N, Cornfield M, Giantonio B, Greenberg R, Gomella L, Litwin S, Ross E, Roethke S, McAleer C (1997) Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. J Clin Oncol 15:3156

    CAS  PubMed  Google Scholar 

  19. Izbicka E, Dalton WS, Troyer D, Von Hoff DD (1998) Expression of two multidrug resistance genes in human prostatic carcinomas. J Natl Cancer Inst 90:166

    CAS  PubMed  Google Scholar 

  20. Kantoff PW, Halabi S, Conaway M, Picus J, Kirshner J, Hars V, Trump D, Winer EP, Vogelzang NJ (1999) Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol 17:2506

    CAS  PubMed  Google Scholar 

  21. Kawai K, Sakurai M, Sakai T, Misaki M, Kusano I, Shiraishi T, Yatani R (2000) Demonstration of MDR1 P-glycoprotein isoform expression in benign and malignant human prostate cells by isoform-specific monoclonal antibodies. Cancer Lett 150:147

    Article  CAS  PubMed  Google Scholar 

  22. Kelly WK, Curley T, Slovin S, Heller G, McCaffrey J, Bajorin D, Ciolino A, Regan K, Schwartz M, Kantoff P, George D, Oh W, Smith M, Kaufman D, Small EJ, Schwartz L, Larson S, Tong W, Scher H (2001) Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer. J Clin Oncol 19:44

    CAS  PubMed  Google Scholar 

  23. Lum BL, Gosland MP (1995) MDR expression in normal tissues. Pharmacologic implications for the clinical use of P-glycoprotein inhibitors. Hematol Oncol Clin North Am 9:319

    CAS  PubMed  Google Scholar 

  24. Oh WK (2000) Chemotherapy for patients with advanced prostate carcinoma: a new option for therapy. Cancer 88:3015

    Article  CAS  PubMed  Google Scholar 

  25. Oh WK, Kantoff PW (1998) Management of hormone refractory prostate cancer: current standards and future prospects. J Urol 160:1220

    CAS  PubMed  Google Scholar 

  26. Oh WK, Kantoff PW (1999) Treatment of locally advanced prostate cancer: is chemotherapy the next step? J Clin Oncol 17:3664

    CAS  PubMed  Google Scholar 

  27. Peck RA, Hewett J, Harding MW, Wang YM, Chaturvedi PR, Bhatnagar A, Ziessman H, Atkins F, Hawkins MJ (2001) Phase I and pharmacokinetic study of the novel MDR1 and MRP1 inhibitor biricodar administered alone and in combination with doxorubicin. J Clin Oncol 19:3130

    CAS  PubMed  Google Scholar 

  28. Petrylak DP, Macarthur RB, O'Connor J, Shelton G, Judge T, Balog J, Pfaff C, Bagiella E, Heitjan D, Fine R, Zuech N, Sawczuk I, Benson M, Olsson CA (1999) Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. J Clin Oncol 17:958

    CAS  PubMed  Google Scholar 

  29. Rowinsky EK, Smith L, Wang YM, Chaturvedi P, Villalona M, Campbell E, Aylesworth C, Eckhardt SG, Hammond L, Kraynak M, Drengler R, Stephenson J Jr, Harding MW, Von Hoff DD (1998) Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP. J Clin Oncol 16:2964

    CAS  PubMed  Google Scholar 

  30. Schummer B, Siegsmund M, Steidler A, Toktomambetova L, Kohrmann KU, Alken P (1999) Expression of the gene for the multidrug resistance-associated protein in human prostate tissue. Urol Res 27:164

    Article  CAS  PubMed  Google Scholar 

  31. Siegsmund MJ, Cardarelli C, Aksentijevich I, Sugimoto Y, Pastan I, Gottesman MM (1994) Ketoconazole effectively reverses multidrug resistance in highly resistant KB cells. J Urol 151:485

    CAS  PubMed  Google Scholar 

  32. Siegsmund MJ, Kreukler C, Steidler A, Nebe T, Kohrmann KU, Alken P (1997) Multidrug resistance in androgen-independent growing rat prostate carcinoma cells is mediated by P-glycoprotein. Urol Res 25:35

    CAS  PubMed  Google Scholar 

  33. Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1

    CAS  PubMed  Google Scholar 

  34. Smith DC, Esper P, Strawderman M, Redman B, Pienta KJ (1999) Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer. J Clin Oncol 17:1664

    CAS  PubMed  Google Scholar 

  35. Sonneveld P (2000) Multidrug resistance in haematological malignancies. J Intern Med 247:521

    Article  CAS  PubMed  Google Scholar 

  36. Speicher LA, Barone LR, Chapman AE, Hudes GR, Laing N, Smith CD, Tew KD (1994) P-glycoprotein binding and modulation of the multidrug-resistant phenotype by estramustine. J Natl Cancer Inst 86:688

    CAS  PubMed  Google Scholar 

  37. Sullivan GF, Amenta PS, Villanueva JD, Alvarez CJ, Yang JM, Hait WN (1998) The expression of drug resistance gene products during the progression of human prostate cancer. Clin Cancer Res 4:1393

    CAS  PubMed  Google Scholar 

  38. Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, Armitage GR, Wilson JJ, Venner PM, Coppin CM, Murphy KC (1996) Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 14:1756

    Google Scholar 

  39. Toppmeyer D, Seidman AD, Pollak M, Russell C, Tkaczuk K, Verma S, Overmoyer B, Garg V, Ette E, Harding MW, Demetri GD (2002) Safety and efficacy of the multidrug resistance inhibitor Incel (biricodar; VX-710) in combination with paclitaxel for advanced breast cancer refractory to paclitaxel. Clin Cancer Res 8:670–678

    CAS  PubMed  Google Scholar 

  40. Van Brussel JP, Van Steenbrugge GJ, Van Krimpen C, Bogdanowicz JF, Van Der Kwast TH, Schroder FH, Mickisch GH (2001) Expression of multidrug resistance related proteins and proliferative activity is increased in advanced clinical prostate cancer. J Urol 165:130

    PubMed  Google Scholar 

  41. Wiseman LR, Spencer CM (1997) Mitoxantrone. A review of its pharmacology and clinical efficacy in the management of hormone-resistant advanced prostate cancer. Drugs Aging 10:473

    CAS  PubMed  Google Scholar 

  42. Yanagisawa T, Newman A, Coley H, Renshaw J, Pinkerton CR, Pritchard-Jones K (1999) BIRICODAR (VX-710; Incel): an effective chemosensitizer in neuroblastoma. Br J Cancer 80:1190

    Article  CAS  PubMed  Google Scholar 

  43. Yang CP, Shen HJ, Horwitz SB (1994) Modulation of the function of P-glycoprotein by estramustine. J Natl Cancer Inst 86:723

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. H. Lee Moffitt Cancer Center, Tampa, FL, USA

    Randall P. Rago, Albert Einstein Jr., Richard Lush & William S. Dalton

  2. Oregon Health and Science University, Portland, OR, USA

    Tomasz M. Beer & W. David Henner

  3. Beth Israel Deaconess Medical Center, Boston, MA, USA

    Yoo-Joung Ko & Glenn Bubley

  4. Vertex Pharmaceuticals Incorporated, 130 Waverly Street, Cambridge, MA 02139, USA

    Elizabeth A. Merica, Varun Garg, Ene Ette & Matthew W. Harding

Authors
  1. Randall P. Rago
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Albert Einstein Jr.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Richard Lush
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tomasz M. Beer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yoo-Joung Ko
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. W. David Henner
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Glenn Bubley
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Elizabeth A. Merica
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Varun Garg
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Ene Ette
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Matthew W. Harding
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. William S. Dalton
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Matthew W. Harding.

Additional information

In addition to the authors named above, the following Principal Investigators also participated in this work: Robert Shepard, Greater Baltimore Medical Center, Baltimore, MD; Gurkmal Chatta, Arkansas Cancer Research Center, Little Rock, AR; Paul Unger, Vermont Center for Cancer Medicine, Burlington, VT.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rago, R.P., Einstein, A., Lush, R. et al. Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer. Cancer Chemother Pharmacol 51, 297–305 (2003). https://doi.org/10.1007/s00280-003-0573-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-003-0573-4

Keywords

Search

Navigation